Filing Flows

Filing Flows › Companies › Charles River Laboratories International › Cash flow

Charles River Laboratories International cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$207M in Q3 2026 · $400M over twelve months

Operating cash flow$254M
Capital spending−$46.8M
Free cash flow+$207M
Cash / net income0.8×

Analysis

In Q3 2026, Charles River Laboratories International generated $254M of operating cash flow and spent $46.8M on capital projects, leaving free cash flow of $207M.

Over the twelve months to Sep 26, 2026, operating cash flow was $622M; the largest uses were acquisitions ($467M), buybacks ($324M), capital spending ($223M); besides operations, cash came from net borrowing (+) / repaid (−) ($288M), asset & business sales ($177M); the cash balance rose by $39.9M.

Operating cash flow was $254M against net income of $334M — 0.8× profit, less cash than reported earnings, worth checking against working capital. The largest differences: depreciation & amortization +$72.3M, employee-related liabilities +$38.0M, receivables −$23.1M.

Free cash flow

Charles River Laboratories International: free cash flow by quarterCharles River Laboratories International: free cash flow by quarter$83.7MQ4 2024$112MQ1 2025$169MQ2 2025$178MQ3 2025$58.6MQ4 2025−$14.8MQ1 2026$149MQ2 2026$207MQ3 2026
Operating cash flow less capital spending.
Charles River Laboratories International: operating cash flow against capital spendingCharles River Laboratories International: operating cash flow against capital spendingOperating cash flowCapital spending$159M$75.6MQ4 2024$172M$59.3MQ1 2025$205M$35.3MQ2 2025$214M$35.6MQ3 2025$148M$89.0MQ4 2025$41.1M$55.9MQ1 2026$180M$31.1MQ2 2026$254M$46.8MQ3 2026
Latest (Q3 2026): Operating cash flow $254M, Capital spending $46.8M.

Capital allocation, year by year

Charles River Laboratories International: where the cash came from (up) and went (down), by fiscal yearCharles River Laboratories International: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow $761MFY2021: Net borrowing $705MFY2021: Shares issued $45.7MFY2021: Asset sales $123MFY2021: Capital spending −$229MFY2021: Acquisitions −$1.3BFY2021: Buybacks −$40.7M$1.6BFY2021FY2022: Operating cash flow $620MFY2022: Net borrowing $17.5MFY2022: Shares issued $25.1MFY2022: Asset sales $163MFY2022: Capital spending −$325MFY2022: Acquisitions −$283MFY2022: Buybacks −$38.7M$826MFY2022FY2023: Operating cash flow $684MFY2023: Net borrowing −$77.6MFY2023: Shares issued $25.6MFY2023: Capital spending −$319MFY2023: Acquisitions −$195MFY2023: Buybacks −$24.2M$709MFY2023FY2024: Operating cash flow $735MFY2024: Net borrowing −$415MFY2024: Shares issued $23.9MFY2024: Capital spending −$233MFY2024: Acquisitions −$5.5MFY2024: Buybacks −$119M$758MFY2024FY2025: Operating cash flow $738MFY2025: Net borrowing −$125MFY2025: Shares issued $714KFY2025: Asset sales $17.4MFY2025: Capital spending −$219MFY2025: Buybacks −$361M$756MFY2025
Over these 5 years operating cash flow totalled $3.5B; the largest uses were acquisitions ($1.8B) and capital spending ($1.3B). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$200M
Debt$2.4B
Net debt$2.2B
Due within a year$1.3M

Charles River Laboratories International funds itself: free cash flow was $400M over the last twelve months, and $200M of cash and investments stands against $2.4B of debt ($1.3M due within a year, 150.2× covered by cash).

Charles River Laboratories International: debt maturities by year (FY2025)Charles River Laboratories International: debt maturities by year (FY2025)$1.3MYear 1$1.5MYear 2$501MYear 3$1.1BYear 4$501MYear 5$1.2MAfter year 5
Principal due in each year as disclosed in the annual report, against $200M of cash and investments now.

Where the cash came from and went

Charles River Laboratories International: sources (+) and uses (−) of cash, Q3 2026Charles River Laboratories International: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$254MNet borrowing (+) / repaid (−)−$180MOther financing−$102MOther investing$57.0MCapital spending−$46.8MShares issued$28.1MCash drawn (+) / kept (−)−$8.5MExchange rates−$1.7MBuybacks−$224K
Charles River Laboratories International: sources (+) and uses (−) of cash, TTM to Q3 2026Charles River Laboratories International: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$622MAcquisitions−$467MBuybacks−$324MNet borrowing (+) / repaid (−)$288MCapital spending−$223MAsset & business sales$177MOther financing−$117MOther investing$51.1MCash drawn (+) / kept (−)−$39.9MShares issued$30.4MExchange rates$2.7M

From profit to cash

Charles River Laboratories International: net income to operating cash flow, Q3 2026Charles River Laboratories International: net income to operating cash flow, Q3 2026Net income$334MDepreciation & amortization$72.3MStock-based pay$20.8MDeferred taxes−$16.2MImpairments$892KGains on disposals$708KOther non-cash$4.1MReceivables−$23.1MInventory$20.7MPayables$4.3MEmployee-related liabilities$38.0MDeferred revenue$634KOther operating capital$22.4MOperating cash flow$254M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowCapital spendingAcquisitionsBuybacksNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$254M−$46.8M—−$224K−$180M$28.1M−$8.5M$207M
Q2 2026$180M−$31.1M−$62.2M−$116M−$37.5M$397K−$42.4M$149M
Q1 2026$41.1M−$55.9M−$405M−$208M$557M$1.2M$17.8M−$14.8M
Q4 2025$148M−$89.0M—−$96K−$51.1M$711K−$6.8M$58.6M
Q3 2025$214M−$35.6M—−$93K−$146M$2K−$24.5M$178M
Q2 2025$205M−$35.3M—−$7.4M−$191M$1K$47.0M$169M
Q1 2025$172M−$59.3M—−$353M$267M—−$26.2M$112M
Q4 2024$159M−$75.6M—−$124K−$72.0M$768K$6.1M$83.7M

Charles River Laboratories International: income statement and cash flow

Charles River Laboratories International, Q3 2026: revenue $983M (-2% year over year), operating margin 20.6%. The chart follows the revenue to costs, profit and cash.

Charles River Laboratories International: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.